(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -12.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Cytomx Therapeutics's revenue in 2024 is $119,178,000.On average, 4 Wall Street analysts forecast CTMX's revenue for 2024 to be $8,281,893,892, with the lowest CTMX revenue forecast at $6,233,549,520, and the highest CTMX revenue forecast at $11,879,119,482. On average, 4 Wall Street analysts forecast CTMX's revenue for 2025 to be $6,952,277,780, with the lowest CTMX revenue forecast at $6,233,549,520, and the highest CTMX revenue forecast at $8,415,291,852.
In 2026, CTMX is forecast to generate $6,416,660,037 in revenue, with the lowest revenue forecast at $6,233,549,520 and the highest revenue forecast at $6,599,770,554.